Pub Date : 2022-09-30DOI: 10.1101/2022.09.29.22280526
R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong
Background: As of December 30, 2021, Ontario long-term care (LTC) residents who received a third dose of COVID-19 vaccine [≥]84 days previously were offered a fourth dose to prevent a surge in COVID-19-related morbidity and mortality due to the Omicron variant. Seven months have passed since fourth doses were implemented, allowing for the examination of fourth dose protection over time. Methods: We used a test-negative design and linked databases to estimate the marginal effectiveness (4 versus 3 doses) and vaccine effectiveness (VE; 2, 3, or 4 doses versus no doses) of mRNA vaccines among Ontario LTC residents aged [≥]60 years who were tested for SARS-CoV-2 between December 30, 2021 and August 3, 2022. Outcome measures included any Omicron infection, symptomatic infection, and severe outcomes (hospitalization or death). Results: We included 21,275 Omicron cases and 273,466 test-negative controls. The marginal effectiveness of a fourth dose <84 days ago compared to a third dose received [≥]84 days ago was 23% (95% Confidence Interval [CI] 17-29%), 36% (95%CI 26-44%), and 37% (95%CI 24-48%) against SARS-CoV-2 infection, symptomatic infection, and severe outcomes, respectively. Additional protection provided by a fourth dose compared to a third dose was negligible against all outcomes [≥]168 days after vaccination. Compared to unvaccinated individuals, vaccine effectiveness (VE) of a fourth dose decreased from 49% (95%CI 44%-54%) to 18% (95%CI 5-28%) against infection, 69% (95%CI 62-75%) to 44% (95%CI 24-59%) against symptomatic infection, and 82% (95%CI 77-86%) to 74% (95%CI 62-82%) against severe outcomes <84 days versus [≥]168 days after vaccination. Conclusions: Our findings suggest that fourth doses of mRNA COVID-19 vaccines provide additional protection against Omicron-related outcomes in LTC residents, but the protection wanes over time, with more waning seen against infection than severe outcomes.
{"title":"Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada","authors":"R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong","doi":"10.1101/2022.09.29.22280526","DOIUrl":"https://doi.org/10.1101/2022.09.29.22280526","url":null,"abstract":"Background: As of December 30, 2021, Ontario long-term care (LTC) residents who received a third dose of COVID-19 vaccine [≥]84 days previously were offered a fourth dose to prevent a surge in COVID-19-related morbidity and mortality due to the Omicron variant. Seven months have passed since fourth doses were implemented, allowing for the examination of fourth dose protection over time. Methods: We used a test-negative design and linked databases to estimate the marginal effectiveness (4 versus 3 doses) and vaccine effectiveness (VE; 2, 3, or 4 doses versus no doses) of mRNA vaccines among Ontario LTC residents aged [≥]60 years who were tested for SARS-CoV-2 between December 30, 2021 and August 3, 2022. Outcome measures included any Omicron infection, symptomatic infection, and severe outcomes (hospitalization or death). Results: We included 21,275 Omicron cases and 273,466 test-negative controls. The marginal effectiveness of a fourth dose <84 days ago compared to a third dose received [≥]84 days ago was 23% (95% Confidence Interval [CI] 17-29%), 36% (95%CI 26-44%), and 37% (95%CI 24-48%) against SARS-CoV-2 infection, symptomatic infection, and severe outcomes, respectively. Additional protection provided by a fourth dose compared to a third dose was negligible against all outcomes [≥]168 days after vaccination. Compared to unvaccinated individuals, vaccine effectiveness (VE) of a fourth dose decreased from 49% (95%CI 44%-54%) to 18% (95%CI 5-28%) against infection, 69% (95%CI 62-75%) to 44% (95%CI 24-59%) against symptomatic infection, and 82% (95%CI 77-86%) to 74% (95%CI 62-82%) against severe outcomes <84 days versus [≥]168 days after vaccination. Conclusions: Our findings suggest that fourth doses of mRNA COVID-19 vaccines provide additional protection against Omicron-related outcomes in LTC residents, but the protection wanes over time, with more waning seen against infection than severe outcomes.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90573292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.
{"title":"Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso","authors":"Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani","doi":"10.32667/ijid.v8i1.134","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.134","url":null,"abstract":"Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81612116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: Vitamin D merupakan salah satu vitamin yang dapat melalui penghambatan respons sel T helper tipe 1 dan merangsang induksi sel T. Hal ini menunjukkan efek perlindungan vitamin D terhadap status infeksi virus pernapasan pada pasien COVID-19. Tujuan: mengetahui hubungan antara kadar Vitamin D dengan derajat penyakit COVID-19. Metode: rancangan penelitian deskriptif korelasional dengan metode analitik melalui pendekatan cross sectional. Total sampel 547 sampel pasien COVID-19 RSPI Sulianti Saroso periode Maret-Desember Tahun 2020. Hasil: Jumlah pasien rawat inap tahun 2020 sebanyak 547 pasien COVID-19, rata-rata usia 47,74 tahun, jenis kelamin laki-laki (55%), dengan komorbid (penyakit penyerta) (58,7%), rata-rata vitamin D 17.94 ng/ml dalam kategori defisiensi < 20 ng/ml (64,2%), derajat keparahan sedang (81,9%). Hasil uji chi square diperoleh nilai p value 0,518 (> 0,05) dengan menggunakan alpha 5% (0,05) berarti tidak ada hubungan antara Vitamin D dengan derajat keparahan pada pasien COVID-19 Kesimpulan: Kadar Vitamin D tidak berhubungan dengan derajat keparahan COVID-19
{"title":"Hubungan Antara Kadar Vitamin D dengan Derajat Keparahan COVID-19","authors":"Handoko Handoko, Angki Purwanti, Dian Wahyu Tanjungsari, I. Pertiwi, Farida Murtiani","doi":"10.32667/ijid.v8i1.130","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.130","url":null,"abstract":"Latar belakang: Vitamin D merupakan salah satu vitamin yang dapat melalui penghambatan respons sel T helper tipe 1 dan merangsang induksi sel T. Hal ini menunjukkan efek perlindungan vitamin D terhadap status infeksi virus pernapasan pada pasien COVID-19. Tujuan: mengetahui hubungan antara kadar Vitamin D dengan derajat penyakit COVID-19. Metode: rancangan penelitian deskriptif korelasional dengan metode analitik melalui pendekatan cross sectional. Total sampel 547 sampel pasien COVID-19 RSPI Sulianti Saroso periode Maret-Desember Tahun 2020. Hasil: Jumlah pasien rawat inap tahun 2020 sebanyak 547 pasien COVID-19, rata-rata usia 47,74 tahun, jenis kelamin laki-laki (55%), dengan komorbid (penyakit penyerta) (58,7%), rata-rata vitamin D 17.94 ng/ml dalam kategori defisiensi < 20 ng/ml (64,2%), derajat keparahan sedang (81,9%). Hasil uji chi square diperoleh nilai p value 0,518 (> 0,05) dengan menggunakan alpha 5% (0,05) berarti tidak ada hubungan antara Vitamin D dengan derajat keparahan pada pasien COVID-19 Kesimpulan: Kadar Vitamin D tidak berhubungan dengan derajat keparahan COVID-19","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81159628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani
Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.
{"title":"Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan","authors":"H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani","doi":"10.32667/ijid.v8i1.135","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.135","url":null,"abstract":"Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87532605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani
Latar Belakang: Penurunan saturasi pada pasien COVID-19 dengan pneumonia dapat dicegah dengan program pemberian posisi salah satunya posisi pronasi. Penelitian ini bertujuan mengetahui pengaruh posisi pronasi terhadap peningkatan saturasi oksigen pada pasien COVID-19 dengan pneumonia. Metode: Quasi eksperimen pretest tanpa kelompok kontrol. Penelitian dilakukan di 2 RS yaitu RSPI Prof Dr Sulianti Saroso dan RSUD Tarakan pada tanggal 8 Maret- 29 April 2021. Jumlah responden sebanyak 24 orang (RSPI SSS: 8 responden dan RS Tarakan: 16 responden). Hasil: Rata-rata pasien adalah laki-laki (19 orang) berusia 55,54 tahun, tidak ada riwayat DM (14 orang) dan memiliki riwayat hipertensi (17 orang). Sebelum intervensi rata-rata SpO2 96.53% dan RR 25.60 x/menit. Sesudah Intervensi rata – rata SpO2 97.36% dan RR 24.59 x/menit. Ada peningkatan nilai SpO2 sebesar 0.83% (Pvalue=0,000), dan ada penurunan RR 1.01 x/menit (Pvalue-0,000). Kesimpulan: ada pengaruh dari penerapan posisi pronasi terhadap peningkatan oksigenasi pada pasien COVID-19 dengan pneumonia.
{"title":"Penerapan Posisi Pronasi Terhadap Peningkatan Oksigenasi Pada Pasien COVID-19 Dengan Pneumonia","authors":"D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani","doi":"10.32667/ijid.v8i1.133","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.133","url":null,"abstract":"Latar Belakang: Penurunan saturasi pada pasien COVID-19 dengan pneumonia dapat dicegah dengan program pemberian posisi salah satunya posisi pronasi. Penelitian ini bertujuan mengetahui pengaruh posisi pronasi terhadap peningkatan saturasi oksigen pada pasien COVID-19 dengan pneumonia. Metode: Quasi eksperimen pretest tanpa kelompok kontrol. Penelitian dilakukan di 2 RS yaitu RSPI Prof Dr Sulianti Saroso dan RSUD Tarakan pada tanggal 8 Maret- 29 April 2021. Jumlah responden sebanyak 24 orang (RSPI SSS: 8 responden dan RS Tarakan: 16 responden). Hasil: Rata-rata pasien adalah laki-laki (19 orang) berusia 55,54 tahun, tidak ada riwayat DM (14 orang) dan memiliki riwayat hipertensi (17 orang). Sebelum intervensi rata-rata SpO2 96.53% dan RR 25.60 x/menit. Sesudah Intervensi rata – rata SpO2 97.36% dan RR 24.59 x/menit. Ada peningkatan nilai SpO2 sebesar 0.83% (Pvalue=0,000), dan ada penurunan RR 1.01 x/menit (Pvalue-0,000). Kesimpulan: ada pengaruh dari penerapan posisi pronasi terhadap peningkatan oksigenasi pada pasien COVID-19 dengan pneumonia.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"16 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78169743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif.
背景:COVID-19已经成为世界卫生问题。炎症标记可作为预习预后的COVID-19和神经丝素ramphocyte Ratio (NLR)。研究目的:确定科维-19患者的ir -6与NLR的联系。方法:交叉设计的定量研究。数据来自于2021年1月至7月期间达摩癌症医院COVID-19患者的医疗记录。共有70名符合纳入和排斥标准的患者样本。数据分析是与spearman相关的univariat和bivariat进行的。结果:70名患者中，大多数是晚期老年人(56-65岁)17(243%)，大多数男性是42(60%)。平均g -6 - 43.34 pg/ml, NLR平均12.73。在患者COVID-19中，il6级与NLR之间存在关联。0.563值。结论:y -6与NLR之间有正相关。il6是用来预测COVID-19预后的生物标记之一，因为它的复写形式非常复杂，无法在简单的实验室中处理。相反，我们的结论是，NLR检查可能是另一种生物标记。
{"title":"Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19","authors":"Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani","doi":"10.32667/ijid.v8i1.132","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.132","url":null,"abstract":"Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif. ","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75892757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-18DOI: 10.1101/2022.07.18.22277741
B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung
Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged [≥]30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.
{"title":"Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine","authors":"B. Cowling, S. Cheng, M. Martín-Sánchez, N. Y. M. Au, K. Chan, John K. C. Li, Lison W C Fung, L. Luk, L. Tsang, D. Ip, Leo L. M. Poon, G. Leung, J. Peiris, N. Leung","doi":"10.1101/2022.07.18.22277741","DOIUrl":"https://doi.org/10.1101/2022.07.18.22277741","url":null,"abstract":"Introduction: Third doses of COVID-19 vaccination provide an important boost to immunity, reducing the risk of symptomatic infection and the risk of severe disease. Third doses have been particularly important for improving protection against variants. However, waning of clinical protection particularly against Omicron has been noted after receipt of third doses. Methods: We administered BNT162b2 as a third dose to adults aged [≥]30 years who had previously received two doses of inactivated vaccination. We collected blood before the third dose and again after one month and six months, and tested sera using a spike receptor binding domain IgG enzyme-linked immunosorbent assay, a surrogate virus neutralization test, and live virus plaque reduction neutralization assay against ancestral virus and Omicron BA.2. Results: We administered BNT162b2 as a third dose to 314 adults. We found robust antibody responses to the ancestral strain at six months after receipt of BNT162b2. Antibody responses to Omicron BA.2 were weaker after the third dose and had declined to a low level by six months. From a small number of participants we observed that natural infection or a fourth dose of vaccination generated similar antibody levels against ancestral virus, but infection generated higher antibody level against Omicron BA.2 than vaccination, suggesting a potential advantage in the breadth of antibody response from hybrid immunity. Conclusions: While antibody levels against the ancestral strain remained robust at six months after the third dose, antibody levels against Omicron BA.2 had fallen to low levels suggesting the potential benefits of a fourth dose.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73918906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Gómez-Carballa, S. Pischedda, I. Rivero-Calle, J. Montoto-Louzao, F. Martinon-Torres, A. Salas
{"title":"CD14 and related genes in respiratory morbidity after Respiratory Syncytial Virus infection.","authors":"A. Gómez-Carballa, S. Pischedda, I. Rivero-Calle, J. Montoto-Louzao, F. Martinon-Torres, A. Salas","doi":"10.1093/infdis/jiac248","DOIUrl":"https://doi.org/10.1093/infdis/jiac248","url":null,"abstract":"","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90410210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-16DOI: 10.1101/2022.06.15.22276439
T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard
Background: More information is needed on prevalence of long-term symptoms after SARS-CoV-2-infection. This prospective study assesses symptoms three months after SARS-CoV-2-infection compared to test-negative and population controls, and the effect of vaccination prior to infection. Methods: Participants enrolled after a positive (cases) or negative (test-negative controls) SARS-CoV-2-test, or after invitation from the general population (population controls). After three months, participants indicated presence of 41 symptoms, and severity of four symptoms. Permutation tests were used to select symptoms significantly elevated in cases compared to controls and to compare symptoms between cases that were vaccinated or unvaccinated prior to infection. Findings: Between May 19th and December 13th 2021 9166 cases, 1698 symptomatic but test-negative controls, and 3708 population controls enrolled. At three months, 13 symptoms, and severity of fatigue, cognitive impairment and dyspnoea, were significantly elevated between cases and controls. Of cases, 48.5% reported [≥]1 significantly elevated symptom, compared to 29.8% of test-negative controls and 26.0% of population controls. Effect of vaccination could only be determined for cases <65yrs, and was found to be significantly protective for loss of smell and taste but not for other symptoms. Interpretation: Three months after SARS-CoV-2 infection, almost half of the cases still report symptoms, which is higher than the background prevalence and prevalence in test-negative controls. Vaccination prior to infection was protective against loss of smell and taste as assessed in cases aged <65.
{"title":"Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in the Netherlands","authors":"T. van der Maaden, Elizabeth N Mutubuki, S. de Bruijn, K. Y. Leung, H. Knoop, Jaap Slootweg, A. D. Tulen, A. Wong, A. V. van Hoek, E. Franz, C. C. van den Wijngaard","doi":"10.1101/2022.06.15.22276439","DOIUrl":"https://doi.org/10.1101/2022.06.15.22276439","url":null,"abstract":"Background: More information is needed on prevalence of long-term symptoms after SARS-CoV-2-infection. This prospective study assesses symptoms three months after SARS-CoV-2-infection compared to test-negative and population controls, and the effect of vaccination prior to infection. Methods: Participants enrolled after a positive (cases) or negative (test-negative controls) SARS-CoV-2-test, or after invitation from the general population (population controls). After three months, participants indicated presence of 41 symptoms, and severity of four symptoms. Permutation tests were used to select symptoms significantly elevated in cases compared to controls and to compare symptoms between cases that were vaccinated or unvaccinated prior to infection. Findings: Between May 19th and December 13th 2021 9166 cases, 1698 symptomatic but test-negative controls, and 3708 population controls enrolled. At three months, 13 symptoms, and severity of fatigue, cognitive impairment and dyspnoea, were significantly elevated between cases and controls. Of cases, 48.5% reported [≥]1 significantly elevated symptom, compared to 29.8% of test-negative controls and 26.0% of population controls. Effect of vaccination could only be determined for cases <65yrs, and was found to be significantly protective for loss of smell and taste but not for other symptoms. Interpretation: Three months after SARS-CoV-2 infection, almost half of the cases still report symptoms, which is higher than the background prevalence and prevalence in test-negative controls. Vaccination prior to infection was protective against loss of smell and taste as assessed in cases aged <65.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91326539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Cutts, Katherine O’Flaherty, S. Zaloumis, E. Ashley, Jo-Anne Chan, M. Onyamboko, Caterina A Fanello, A. Dondorp, Nicholas P J Day, A. Phyo, M. Dhorda, M. Imwong, R. Fairhurst, Pharath Lim, C. Amaratunga, S. Pukrittayakamee, T. Hien, Y. Htut, M. Mayxay, M. Faiz, E. Takashima, T. Tsuboi, J. Beeson, F. Nosten, J. Simpson, N. White, F. Fowkes
Abstract Background Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.
{"title":"Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia","authors":"J. Cutts, Katherine O’Flaherty, S. Zaloumis, E. Ashley, Jo-Anne Chan, M. Onyamboko, Caterina A Fanello, A. Dondorp, Nicholas P J Day, A. Phyo, M. Dhorda, M. Imwong, R. Fairhurst, Pharath Lim, C. Amaratunga, S. Pukrittayakamee, T. Hien, Y. Htut, M. Mayxay, M. Faiz, E. Takashima, T. Tsuboi, J. Beeson, F. Nosten, J. Simpson, N. White, F. Fowkes","doi":"10.1093/infdis/jiac232","DOIUrl":"https://doi.org/10.1093/infdis/jiac232","url":null,"abstract":"Abstract Background Understanding the effect of immunity on Plasmodium falciparum clearance is essential for interpreting therapeutic efficacy studies designed to monitor emergence of artemisinin drug resistance. In low-transmission areas of Southeast Asia, where resistance has emerged, P. falciparum antibodies confound parasite clearance measures. However, variation in naturally acquired antibodies across Asian and sub-Saharan African epidemiological contexts and their impact on parasite clearance re yet to be quantified. Methods In an artemisinin therapeutic efficacy study, antibodies to 12 pre-erythrocytic and erythrocytic P. falciparum antigens were measured in 118 children with uncomplicated P. falciparum malaria in the Democratic Republic of Congo (DRC) and compared with responses in patients from Asian sites, described elsewhere. Results Parasite clearance half-life was shorter in DRC patients (median, 2 hours) compared with most Asian sites (median, 2–7 hours), but P. falciparum antibody levels and seroprevalences were similar. There was no evidence for an association between antibody seropositivity and parasite clearance half-life (mean difference between seronegative and seropositive, −0.14 to +0.40 hour) in DRC patients. Conclusions In DRC, where artemisinin remains highly effective, the substantially shorter parasite clearance time compared with Asia was not explained by differences in the P. falciparum antibody responses studied.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"65 1","pages":"324 - 331"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85800569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：